Tests RO7673396 in adults with advanced solid tumors carrying RAS mutations
Tests the drug RO7673396 in adults with advanced solid tumors that have RAS mutations.
Key facts
- Who runs it
- Hoffmann-La Roche
- Where
- Hong Kong, Hong KongSee the siteAlso in 10 other countries, 24 sites
- Trial code
- Registry title
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 405 people, planned
- Started
- 30 Apr 2025
- Expected to end
- 25 May 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- RO7673396
- Record updated
- 28 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced solid tumors that cannot be cured and that carry a RAS mutation. It tests the safety of the drug RO7673396.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Locally advanced, recurrent or metastatic solid tumors that cannot be cured, with disease that can be measured by RECIST v1.1
- Earlier treatment
- No chemotherapy, immunotherapy, biologic therapy or investigational anti-cancer drug within 4 weeks or five half-lives before starting study treatment
- Biomarker or test result
- Confirmed RAS mutation(s)
Main reasons for not taking part
- Taking part in another interventional clinical trial
- Known or active brain or spinal cord (CNS) metastases that are untreated
- History of lung scarring or inflammation (pulmonary fibrosis, pneumonitis, ILD)
- Bowel problems that stop the drug being absorbed (such as chronic diarrhea, short bowel syndrome, inflammatory bowel disease)
- Major surgery within 28 days before starting study treatment
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Histologically documented, locally advanced, recurrent, or metastatic incurable solid tumors
- Participants with measurable disease according to RECIST v1.1 assessed by the investigator
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy ≥12 weeks
- Adequate hematologic and end-organ function
- Confirmed presence of the RAS mutation(s)
Who cannot take part
- Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant small bowel resection that would preclude adequate study treatment absorption
- Treatment with chemotherapy, immunotherapy, biologic therapy, or an investigational agent as anti-cancer therapy within 4 weeks or five half-lives prior to initiation of study treatment
- Major surgical procedure within 28 days prior to initiation of study treatment, or incomplete recovery from surgery that would interfere with the determination of safety or efficacy of study treatment, or anticipation of need for a major surgical procedure during the study
- Known hypersensitivity or medical contraindication to any component of RO7673396 formulation
- Participants with chronic diarrhea, short bowel syndrome or significant upper gastrointestinal (GI) surgery including gastric resection, a history of inflammatory bowel disease (IBD)
- A history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, non-infectious ILD/pneumonitis, or current evidence of active pneumonitis or ILD on screening chest CT scan
- Known clinically significant liver disease
- Current participant or enrollment in another interventional clinical trial
- Known and untreated, or active central nervous system (CNS) metastases
- Participants who are on acid-reducing agents and unable to safely discontinue them as required in the study
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
Where in Hong Kong
Also in 10 other countries, 24 sites
- Prince of Wales HospitalHong Kong, Hong KongTaking people
About the trial
What the trial wants to find out
This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of RO7673396. Stage 2 will evaluate preliminary anti-tumor activity of the RDE(s) defined in Stage 1 and of other doses of interest for future development in selected solid tumor indications.
The 2 groups in the trial
- Stage ITreatment being tested
Participants with advanced solid tumors harboring RAS mutations will receive multiple ascending doses of RO7673396, as per a pre-defined dosing regimen until unacceptable toxicity or disease progression (PD) and/or loss of clinical benefit as determined by the investigator.
Treatment: RO7673396
- Stage IITreatment being tested
Participants with advanced solid tumors harboring RAS mutations will receive RO7673396 at the dose determined in Stage 1, until unacceptable toxicity or PD and/or loss of clinical benefit as determined by the investigator.
Treatment: RO7673396
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)
- Plain-language title
- Tests RO7673396 in adults with advanced solid tumors carrying RAS mutationsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 28 September 2026